Dale Shepard MD, PhD retweetledi

In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: nej.md/3OIQC5P
Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors nej.md/3N0pQW8

English



















